Proinflammatory cytokines and their role in the development of major transplant-related complications in the early phase after allogeneic bone marrow transplantation

Leukemia

Volumn 17, Issue 6, 2003, Pages 1150-1156

  Schots, R ^a   Kaufman, L ^a   Van Riet, I ^a   Othman, T Ben ^a   De Waele, M ^a   Van Camp, B ^a   Demanet, C ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Allogeneic marrow transplantation; Interleukin 6; Interleukin 8; Major complications; Tumor necrosis factor alpha

Indexed keywords

C REACTIVE PROTEIN; CYCLOSPORIN; CYTOKINE; DIURETIC AGENT; DOPAMINE; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; HEPARIN; INTERLEUKIN 6; INTERLEUKIN 8; ITRACONAZOLE; METHOTREXATE; NORFLOXACIN; NYSTATIN; POVIDONE IODINE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRAFT REJECTION; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ANEMIA; ARTICLE; BACTEREMIA; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE RELEASE; ENDOTHELIUM LESION; FEMALE; FLUID RETENTION; GRAFT VERSUS HOST REACTION; HUMAN; LEUKEMIA; LIVER VENOOCCLUSIVE DISEASE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MYELODYSPLASIA; MYELOMA; PNEUMONIA; PRIORITY JOURNAL; PROTEIN FUNCTION; RISK ASSESSMENT; SOLID TUMOR;

EID: 0038378818     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402946     Document Type: Article

References (42)

1. Carreras E, Bertz H, Arcese W, Vernant JP, Tomas JF, Hagglund H et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 1998; 92: 3599-3604.
2. Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995; 85: 3005-3020.
3. Kantrow SP, Hackman RC, Boeckh M, Myerson D, Crawford SW. Idiopathic pneumonia syndrome: changing spectrum of lung injury after marrow transplantation. Transplantation 1997; 63: 1079-1086.
4. Cahill RA, Spitzer TR, Mazumder A. Marrow engraftment and clinical manifestations of capillary leak syndrome. Bone Marrow Transplant 1996; 18: 177-184.
5. Schots R, Kaufman L, Van Riet I, Lacor P, Trullemans F, De Waele M et al. Monitoring of C-reactive protein after allogeneic bone marrow transplantation identifies patients at risk of severe transplant-related complications and mortality. Bone Marrow Transplant 1998; 22: 79-85.
6. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-454.
7. Antin JH, Ferrara JL. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 80: 2964-2968.
8. Gugliotta L, Catani L, Vianelli N, Gherlinzoni F, Miggiano MC, Bandini G et al. High plasma levels of tumor necrosis factor-alpha may be predictive of veno-occlusive disease in bone marrow transplantation. Blood 1994; 83: 2385-2386.
9. Holler E, Kolb HJ, Moller A, Kempeni J, Liesenfeld S, Pechumer H et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 1990; 75: 1011-1016.
10. Remberger M, Ringden O. Serum levels of cytokines after bone marrow transplantation: increased IL-8 levels during severe veno-occlusive disease of the liver. EurJ Haematol 1997; 59: 254-262.
11. Symington FW, Symington BE, Liu PY, Viguet H, Santhanam U, Sehgal PB. The relationship of serum IL-6 levels to acute graft-versus-host disease and hepatorenal disease after human bone marrow transplantation. Transplantation 1992; 54: 457-462.
12. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255-267.
13. Clark JG, Madtes DK, Martin TR, Hackman RC, Farrand AL, Crawford SW. Idiopathic pneumonia after bone marrow transplantation: cytokine activation and lipopolysaccharide amplification in the bronchoalveolar compartment. Crit Care Med 1999; 27: 1800-1806.
14. Gaynor ER, Vitek L, Sticklin L, Creekmore SP, Ferraro ME, Thomas Jr JX et al. The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 1988; 109: 953-958.
15. Thijs LG, Hack CE, Strack van Schijndel RJ, Nuijens JH, Wolbink GJ, Eerenberg-Belmer AJ et al. Activation of the complement system during immunotherapy with recombinant IL-2. Relation to the development of side effects. J Immunol 1990; 144: 2419-2424.
16. Storb R, Thomas ED. Graft-versus-host disease in dog and man: the Seattle experience. Immunol Rev 1985; 88: 215-238.
17. Schots R, Trullemans F, Van Riet I, Kaufman L, Hafsia A, Meddeb B et al. The clinical impact of early gram-positive bacteremia and the use of vancomycin after allogeneic bone marrow transplantation. Transplantation 2000; 69: 1511-1514.
18. Castell JV, Gomez-Lechon MJ, David M, Fabra R, Trullenque R, Heinrich PC. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology 1990; 12: 1179-1186.
19. Vachino G, Gelfand JA, Atkins MB, Tamerius JD, Demchak P, Mier JW. Complement activation in cancer patients undergoing immunotherapy with interleukin-2 (IL-2): binding of complement and C-reactive protein by IL-2-activated lymphocytes. Blood 1991; 78: 2505-2513.
20. Charreau B, Coupel S, Goret F, Pourcel C, Soulillou JP. Association of glucocorticoids and cyclosporin A or rapamycin prevents Eselectin and IL-8 expression during LPS- and TNFalpha-mediated endothelial cell activation. Transplantation 2000; 69: 945-953.
21. Faioni EM, Krachmalnicoff A, Bearman SI, Federici AB, Decarli A, Gianni AM et al. Naturally occurring anticoagulants and bone marrow transplantation: plasma protein C predicts the development of venocclusive disease of the liver. Blood 1993; 81:3458-3462.
22. Lee JH, Lee KH, Kim S, Lee JS, Kim WK, Park CJ et al. Relevance of proteins C and S, antithrombin III, von Willebrand factor, and factor VIII for the development of hepatic veno-occlusive disease in patients undergoing allogeneic bone marrow transplantation: a prospective study. Bone Marrow Transplant 1998; 22: 883-888.
23. Rio B, Bauduer F, Arrago JP, Zittoun R. N-terminal peptide of type III procollagen: a marker for the development of hepatic veno-occlusive disease after BMT and a basis for determining the timing of prophylactic heparin. Bone Marrow Transplant 1993; 11: 471-472.
24. Tanikawa S, Mori S, Ohhashi K, Akiyama H, Sasaki T, Kaku H et al. Predictive markers for hepatic veno-occlusive disease after hematopoietic stem cell transplantation in adults: a prospective single center study. Bone Marrow Transplant 2000; 26: 881-886.
25. Fried MW, Duncan A, Soroka S, Connaghan DG, Farrand A, Peter J et al. Serum hyaluronic acid in patients with veno-occlusive disease following bone marrow transplantation. Bone Marrow Transplant 2001; 27: 635-639.
26. van Hinsbergh VW, Bauer KA, Kooistra T, Kluft C, Dooijewaard G, Sherman ML et al. Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products. Blood 1990; 76: 2284-2289.
27. Salat C, Holler E, Kolb HJ, Reinhardt B, Pihusch R, Wilmanns W et al. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation. Blood 1997; 89: 2184-2188.
28. Donnelly SC, Strieter RM, Kunkel SL, Walz A, Robertson CR, Carter DC et al. Interleukin-8 and development of adult respiratory distress syndrome in at-risk patient groups. Lancet 1993; 341: 643-647.
29. Ferrara JL. Pathogenesis of acute graft-versus-host disease: cytokines and cellular effectors. J Hematother Stem Cell Res 2000; 9: 299-306.
30. Khoury H, Adkins D, Brown R, Trinkaus K, Vij R, Miller G, Goodnough LT et al. Does early treatment with high-dose methylprednisolone alter the course of hepatic regimen-related toxicity? Bone Marrow Transplant 2000; 25: 737-743.
31. Chopra R, Eaton JD, Grassi A, Potter M, Shaw B, Salat C et al. Defibroticle for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol 2000;111:1122-1129.
32. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
33. Bacigalupo A, Oneto R, Lamparelli T, Gualandi F, Bregante S, Raiola AM et al. Pre-emptive therapy of acute graft-versus-host disease: a pilot study with antithymocyte globulin (ATG). Bone Marrow Transplant JID-8702459 2001; 28: 1093-1096.
34. Carpenter PA, Appelbaum FR, Corey L, Deeg HJ, Doney K, Gooley T et al. A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood 2002; 99: 2712-2719.
35. Deeg HJ, Blazar BR, Bolwell BJ, Long GD, Schuening F, Cunningham J et al. Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABXCBL. Blood 2001; 98: 2052-2058.
36. Herve P, Flesch M, Tiberghien P, Wijdenes J, Racadot E, Bordigoni P et al. Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease. Blood 1992; 79: 3362-3368.
37. Holler E, Kolb HJ, Mittermuller J, Kaul M, Ledderose G, Duell T et al. Modulation of acute graft-versus-host-disease after al logeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F). Blood, 1995; 86: 890-899.
38. Tse JC, Moore TB. Monoclonal antibodies in the treatment of steroid-resistant acute graft-versus-host disease. Pharmacotherapy 1998; 18: 988-1000.
39. Kobbe G, Schneider P, Rohr U, Fenk R, Neumann F, Aivado M et al. Treatment of severe steroid refractory acute graft-versus- host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody. Bone Marrow Transplant 2001; 28: 47-49.
40. Przepiorka D, Kernan NA, Ippoliti C, Papadopoulos EB, Giralt S, Khouri I et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000; 95: 83-89.
41. Verbon A, Dekkers PE, ten Hove T, Hack CE, Pribble JP, Turner T et al. IC14, an anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans. J Immunol 2001; 166: 3599-3605.
42. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 1997; 90: 3204-3213.